Changes in Beneficial Ownership · 4
TransMedics Group, Inc.
TMDXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-10
- Issuer
- TransMedics Group, Inc.
- Issuer CIK
- 0001756262
- Trading symbol
- TMDX
Reporting owner 1
- Name
- Hassanein Waleed H
- Reporting owner CIK
- 0001430466
- Relationship
- Director · Officer
- Officer title
- President & CEO
- Address
- C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-10 | A · Form 4[F1] | 49,669 | A | 0 | 171,093 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 345,009[F2] | I | By the Waleed H. Hassanein Revocable Trust |
| Common Stock | 150,000[F2] | I | By the Hassanein 2026 Qualified Annuity Trust |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 71.23 | 2026-07-10 | A · Form 4 | 112,984 | A | 0 | [F3] | 2036-07-10 | Common Stock | 112,984 | 112,984 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.↩ 1
- F2
- Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.↩ 1↩ 2
- F3
- The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.↩ 1
Signature 1
- Signed
- By: /s/ Gerardo Hernandez, Attorney-in-Fact
- Date
- 2026-07-14
Company context
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. TransMedics routinely posts information that may be important to investors on the landing page of the Company's website and in the "Investors" section of the website at https://investors.transmedics.com/. Investors and potential investors are encouraged to consult the TransMedics website regularly for important information about TransMedics.